2
RESEARCH METHODOLOGY
31
5
MARKET OVERVIEW
Rising organ transplants drive market growth amid challenges of cost, organ shortages, and regulatory complexities.
51
5.2.1.1
RISING NUMBER OF ORGAN DONORS AND TRANSPLANT PROCEDURES
5.2.1.2
SURGE IN ORGAN FAILURE CASES DUE TO INCREASED PREVALENCE OF CHRONIC DISEASES
5.2.1.3
INCREASING RESEARCH ACTIVITIES AND RISING FUNDING FOR ORGAN TRANSPLANTATIONS
5.2.1.4
GROWING ADOPTION OF HLA TYPING IN PERSONALIZED MEDICINES
5.2.2.1
HIGH COSTS OF HLA TYPING PRODUCTS
5.2.2.2
SHORTAGE OF HEALTHY ORGANS FOR TRANSPLANTS
5.2.3.1
ADOPTION OF NGS AND AUTOMATION FOR HIGH-THROUGHPUT NEEDS
5.2.3.2
USE OF AI AND ML IN HLA TYPING FOR BETTER ACCURACY AND BROADER CLINICAL UTILITY
5.2.4.1
REGULATORY COMPLEXITIES ACROSS REGIONS
5.2.4.2
LACK OF STANDARDIZATION ACROSS HLA TYPING LABORATORIES
5.3.1
REGULATORY FRAMEWORK
5.3.1.5
MIDDLE EAST & AFRICA
5.3.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.4.1
RESEARCH & DEVELOPMENT
5.4.2
RAW MATERIAL PROCUREMENT & PRODUCT DEVELOPMENT
5.4.3
MARKETING, SALES, AND DISTRIBUTION, AND AFTERMARKET SERVICE
5.5
SUPPLY CHAIN ANALYSIS
5.5.1
PROMINENT COMPANIES
5.5.2
SMALL AND MEDIUM-SIZED ENTERPRISES
5.5.3
SALES & DISTRIBUTION AGENTS
5.7.1
IMPORT SCENARIO FOR HS CODE 3822, 2020–2024
5.7.2
EXPORT SCENARIO FOR HS CODE 3822, 2020–2024
5.8.1
LIST OF MAJOR PATENTS/PATENT APPLICATIONS
5.9.1
AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY TYPE, 2023–2024
5.9.2
AVERAGE SELLING PRICING TREND OF NEXT-GENERATION SEQUENCING INSTRUMENTS, BY KEY PLAYER, 2023–2024
5.9.3
AVERAGE SELLING PRICING TREND OF REAGENTS, BY TYPE, 2022–2024
5.10.1.1
NEXT-GENERATION SEQUENCING
5.10.1.2
PCR-SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBES
5.10.2
COMPLEMENTARY TECHNOLOGIES
5.10.2.1
SINGLE ANTIGEN-BASED ASSAYS
5.10.2.2
FLOW CYTOMETRY CROSSMATCH
5.10.3
ADJACENT TECHNOLOGIES
5.10.3.1
BIOINFORMATICS SOFTWARE
5.11
PORTER’S FIVE FORCE ANALYSIS
5.11.1
THREAT OF NEW ENTRANTS
5.11.2
THREAT OF SUBSTITUTES
5.11.3
BARGAINING POWER OF SUPPLIERS
5.11.4
BARGAINING POWER OF BUYERS
5.11.5
INTENSITY OF COMPETITIVE RIVALRY
5.12
KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2
KEY BUYING CRITERIA
5.13
KEY CONFERENCES & EVENTS IN 2024–2025
5.14.1
THERMO FISHER SCIENTIFIC TO DEVELOP TECHNIQUES FOR ENHANCING HLA TYPING ACCURACY IN TRANSPLANTATION
5.14.2
ILLUMINA TO STREAMLINE HLA TYPING WITH TRUSIGHT HLA SOLUTION
5.14.3
WERFEN TO ACCELERATE HLA TYPING WITH NANOPORE SEQUENCING
5.15
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.16
INVESTMENT & FUNDING SCENARIO
5.18
IMPACT OF AI/GEN AI ON HLA TYPING FOR TRANSPLANT MARKET
5.18.1
MARKET POTENTIAL OF HLA TYPING PRODUCTS FOR PRE-TRANSPLANT EVALUATION
5.18.1.1
AI USE CASES IN HLA TYPING FOR TRANSPLANT MARKET
5.18.1.2
KEY COMPANIES IMPLEMENTING AI
5.18.2
FUTURE OF AI IN HLA TYPING FOR TRANSPLANT MARKET
5.19
IMPACT OF 2025 US TARIFF ON HLA TYPING FOR TRANSPLANT MARKET
5.19.3
PRICE IMPACT ANALYSIS
5.19.4
IMPACT ON COUNTRY/REGION
5.19.5
IMPACT ON END-USE INDUSTRIES
6
HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 4 Data Tables
88
6.2
REAGENTS & CONSUMABLES
6.2.1
AVAILABILITY OF MULTIPLE VARIETIES OF REAGENTS & CONSUMABLES TO DRIVE ADOPTION IN HLA TYPING PHASES
6.3.1
NEED FOR PRECISE AND RELIABLE HLA MATCHING IN BONE MARROW AND ORGAN TRANSPLANTS TO PROPEL MARKET GROWTH
6.4.1
GROWING AUTOMATION AND DIGITALIZATION OF DIAGNOSTIC LABORATORY PROCEDURES TO AID MARKET GROWTH
7
HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 16 Data Tables
93
7.2.1
PCR-BASED MOLECULAR ASSAYS
7.2.1.1
SEQUENCE-SPECIFIC PRIMER-PCR
7.2.1.2
SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR
7.2.1.4
OTHER PCR-BASED MOLECULAR ASSAYS
7.3
SEQUENCING-BASED MOLECULAR ASSAYS
7.3.1.1
HIGH ACCURACY AND SINGLE-BASE RESOLUTION TO DETECT ALLELIC VARIANTS AND CONFIRM NOVEL OR RARE ALLELES
7.3.2
NEXT-GENERATION SEQUENCING
7.3.2.1
GROWING RELIANCE ON OUTSOURCING IN-HOUSE ANALYSIS TO PROPEL DEMAND IN TISSUE TYPING
7.3.3
OTHER SEQUENCING-BASED MOLECULAR ASSAYS
7.4.1
LOWER COSTS AND HIGHER SPECIFICITY TO DRIVE ADOPTION OVER MOLECULAR ASSAYS
8
HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 7 Data Tables
106
8.2
DIAGNOSTIC APPLICATIONS
8.2.1.1
ADVANCEMENT IN PRE-TRANSPLANT COMPATIBILITY SCREENING WITH NGS TO AID SEGMENT GROWTH
8.2.2
CHIMERISM MONITORING
8.2.2.1
GROWING TREND OF PERSONALIZED TRANSPLANT MEDICINE FOR EFFECTIVE POST-PROCEDURAL CLINICAL RISK MANAGEMENT TO FUEL ADOPTION
8.2.3
OTHER DIAGNOSTIC APPLICATIONS
8.3
RESEARCH APPLICATIONS
8.3.1
INCREASING PUBLIC-PRIVATE INVESTMENTS FOR TRANSPLANT DIAGNOSTICS RESEARCH TO FAVOR MARKET GROWTH
9
HLA TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 4 Data Tables
112
9.2
SOLID ORGAN TRANSPLANTS
9.2.1
HIGH POPULARITY OF ORGAN DONATION AND FAVORABLE GOVERNMENT INITIATIVES TO DRIVE MARKET
9.3
SOFT-TISSUE TRANSPLANTS
9.3.1
NEED FOR HLA TYPING IN COMPOSITE TISSUE ALLOTRANSPLANTATION TO AID ADOPTION
9.4
STEM CELL TRANSPLANTS
9.4.1
EXPANDING DIVERSITY OF DONOR REGISTRIES TO FUEL ADOPTION OF HLA TYPING
10
HLA TYPING FOR TRANSPLANT MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 4 Data Tables
117
10.2
INDEPENDENT REFERENCE LABORATORIES
10.2.1
ADHERENCE TO QUALITY AND REGULATORY STANDARDS WITH HIGH-QUALITY SERVICES TO DRIVE MARKET GROWTH
10.3
HOSPITALS & TRANSPLANT CENTERS
10.3.1
DEVELOPED HEALTHCARE INFRASTRUCTURE AND HIGH SUCCESS RATES IN TRANSPLANT PROCEDURES TO DRIVE MARKET
10.4
RESEARCH LABORATORIES & ACADEMIC INSTITUTES
10.4.1
INCREASING COLLABORATIONS TO DEVELOP AND OPTIMIZE HLA TYPING FOR BETTER ACCURACY, SPECIFICITY, AND EFFICIENCY
11
HLA TYPING FOR TRANSPLANT MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 14 Countries | 103 Data Tables.
122
11.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2.1
US TO DOMINATE HLA TYPING FOR TRANSPLANT MARKET DURING FORECAST PERIOD
11.2.3.1
RISING NUMBER OF SOLID ORGAN AND HEMATOPOIETIC STEM CELL TRANSPLANTS TO DRIVE MARKET ADOPTION OF HLA TYPING
11.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2.1
HIGH DONOR REGISTRATION RATES AND FAVORABLE GOVERNMENT INITIATIVES TO AUGMENT MARKET GROWTH
11.3.3.1
STRONG HEALTHCARE INFRASTRUCTURE AND CENTRALLY COORDINATED TRANSPLANT SYSTEM TO FOSTER GROWTH
11.3.4.1
GROWING ADOPTION FOR DONOR-RECIPIENT COMPATIBILITY TESTING TO SUPPORT MARKET
11.3.5.1
INCREASING POPULARITY OF SOLID ORGAN DONATION TO DRIVE MARKET
11.3.6.1
SUPPORTIVE GOVERNMENT POLICIES AND STRONG HEALTHCARE INFRASTRUCTURE TO SPUR MARKET GROWTH
11.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2.1
PRESENCE OF LEADING GLOBAL MANUFACTURERS OF HLA TYPING PRODUCTS TO DRIVE MARKET
11.4.3.1
RISE IN TRANSPLANTATION PROCEDURES AND USE OF HLA TYPING FOR ASSESSING DONOR-RECIPIENT COMPATIBILITY TO SPUR MARKET GROWTH
11.4.4.1
INCREASING NUMBER OF SOLID ORGAN TRANSPLANTATION PROCEDURES AND RISING CHRONIC DISEASES TO FAVOR MARKET GROWTH
11.4.5.1
INCREASING USE OF GENOMIC TESTING AND ANALYSIS AND GROWING GOVERNMENT BACKING FOR CLINICAL DIAGNOSTICS TO DRIVE MARKET
11.4.6.1
GOVERNMENT SUPPORT AND ADVANCED HEALTHCARE TO DRIVE ADOPTION OF NGS HLA TYPING FOR BETTER TRANSPLANT OUTCOMES
11.4.7
REST OF ASIA PACIFIC
11.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2.1
GROWING ELDERLY DEMOGRAPHIC AND INCREASING FUNDING FROM LEADING HLA TYPING MANUFACTURERS TO PROPEL MARKET GROWTH
11.5.3.1
WIDE RECIPIENT BASE FOR ORGAN TRANSPLANT AND RISE IN MEDICAL TOURISM TO FUEL MARKET GROWTH
11.5.4
REST OF LATIN AMERICA
11.6
MIDDLE EAST & AFRICA
11.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11.6.2.1
IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE AND FOCUS ON SPECIALIZED MEDICAL SERVICES TO AUGMENT MARKET GROWTH
11.6.3
REST OF MIDDLE EAST & AFRICA
12
COMPETITIVE LANDSCAPE
Discover market leaders and emerging contenders shaping the HLA typing for transplant landscape.
177
12.2
KEY PLAYER STRATEGY/RIGHT TO WIN
12.2.1
OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HLA TYPING FOR TRANSPLANT MARKET
12.3
REVENUE ANALYSIS, 2020–2024
12.4
MARKET SHARE ANALYSIS, 2024
12.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.5.5.1
COMPANY FOOTPRINT
12.5.5.2
REGION FOOTPRINT
12.5.5.3
PRODUCT & SERVICE FOOTPRINT
12.5.5.4
TECHNOLOGY FOOTPRINT
12.5.5.5
APPLICATION FOOTPRINT
12.5.5.6
END-USER FOOTPRINT
12.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.6.1
PROGRESSIVE COMPANIES
12.6.2
RESPONSIVE COMPANIES
12.6.5
COMPANY BENCHMARKING: STARTUPS/SMES, 2024
12.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
12.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
12.7
COMPANY VALUATION & FINANCIAL METRICS
12.8
BRAND/PRODUCT COMPARISON
12.9
COMPETITIVE SCENARIO
12.9.1
PRODUCT LAUNCHES AND APPROVALS
13
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
197
13.1.1
THERMO FISHER SCIENTIFIC INC.
13.1.1.1
BUSINESS OVERVIEW
13.1.1.2
PRODUCTS/SERVICES/SOLUTIONS OFFERED
13.1.1.3
RECENT DEVELOPMENTS
13.1.4
BIO-RAD LABORATORIES, INC.
13.1.5
F. HOFFMANN-LA ROCHE LTD.
13.1.9
TBG BIOTECHNOLOGY CORP.
13.1.11
BECTON, DICKINSON AND COMPANY
13.1.12
EUROBIO SCIENTIFIC
13.1.14
BAG DIAGNOSTICS GMBH
13.2.2
SCISCO GENETICS, INC.
13.2.3
INNO-TRAIN DIAGNOSTIK GMBH
13.2.6
KRISHGEN BIOSYSTEMS
13.2.7
SCIENCELL RESEARCH LABORATORIES, INC.
13.2.9
ALPHA BIOTECH LIMITED
13.2.10
BIOFORTUNA LIMITED
14.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3
CUSTOMIZATION OPTIONS
TABLE 1
HLA TYPING FOR TRANSPLANT MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2
HLA TYPING FOR TRANSPLANT MARKET ASSUMPTIONS
TABLE 3
HLA TYPING FOR TRANSPLANT MARKET: RISK ANALYSIS
TABLE 4
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8
HLA TYPING MARKET: ROLE IN ECOSYSTEM
TABLE 9
HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR HS CODE 3822, BY COUNTRY, 2020–2024 (USD THOUSAND)
TABLE 10
HLA TYPING FOR TRANSPLANT MARKET: EXPORT SCENARIO FOR HS CODE 3822, BY COUNTRY, 2020–2024 (USD THOUSAND)
TABLE 11
HLA TYPING FOR TRANSPLANT MARKET: LIST OF MAJOR PATENTS/ PATENT APPLICATIONS
TABLE 12
AVERAGE SELLING PRICING TREND OF NEXT-GENERATION SEQUENCING INSTRUMENTS, BY KEY PLAYER, 2023–2024 (USD)
TABLE 13
AVERAGE SELLING PRICING TREND OF INSTRUMENTS AND REAGENTS, BY REGION, 2022–2024 (USD THOUSAND)
TABLE 14
HLA TYPING FOR TRANSPLANT MARKET: PORTERS FIVE FORCES
TABLE 15
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
TABLE 16
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR MAJOR END USERS
TABLE 17
HLA TYPING FOR TRANSPLANT MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026
TABLE 18
THERMO FISHER SCIENTIFIC TO DEVELOP TECHNIQUES FOR ENHANCING HLA TYPING ACCURACY IN TRANSPLANTATION
TABLE 19
ILLUMINA TO STREAMLINE HLA TYPING WITH TRUSIGHT HLA SOLUTION
TABLE 20
WERFEN TO ACCELERATE HLA TYPING WITH NANOPORE SEQUENCING
TABLE 21
HLA TYPING FOR TRANSPLANT MARKET: UNMET NEEDS
TABLE 22
HLA TYPING FOR TRANSPLANT MARKET: KEY COMPANIES IMPLEMENTING AI
TABLE 23
US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 24
HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 25
HLA TYPING FOR TRANSPLANT MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023–2030 (USD MILLION)
TABLE 26
HLA TYPING FOR TRANSPLANT MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 27
HLA TYPING FOR TRANSPLANT MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023–2030 (USD MILLION)
TABLE 28
HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 29
HLA TYPING FOR TRANSPLANT TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 30
HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 31
HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY REGION, 2023–2030 (USD MILLION)
TABLE 32
PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 33
PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 34
SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 35
SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 36
REAL-TIME PCR MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 37
OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 38
SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 39
SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 40
SANGER SEQUENCING MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 41
NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 42
OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 43
HLA TYPING FOR TRANSPLANT MARKET FOR NON-MOLECULAR ASSAYS, BY REGION, 2023–2030 (USD MILLION)
TABLE 44
HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 45
HLA TYPING FOR TRANSPLANT MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 46
HLA TYPING FOR TRANSPLANT MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 47
ANTIBODY SCREENING MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 48
CHIMERISM MONITORING MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 49
OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 50
HLA TYPING FOR TRANSPLANT MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 51
HLA TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2023–2030 (USD MILLION)
TABLE 52
HLA TYPING FOR SOLID ORGAN TRANSPLANTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 53
HLA TYPING FOR SOFT-TISSUE TRANSPLANTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 54
HLA TYPING FOR STEM CELL TRANSPLANTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 55
HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 56
HLA TYPING FOR TRANSPLANT MARKET FOR INDEPENDENT REFERENCE LABORATORIES, 2023–2030 (USD MILLION)
TABLE 57
HLA TYPING FOR TRANSPLANT MARKET FOR HOSPITALS & TRANSPLANT CENTERS, 2023–2030 (USD MILLION)
TABLE 58
HLA TYPING FOR TRANSPLANT MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, 2023–2030 (USD MILLION)
TABLE 59
HLA TYPING FOR TRANSPLANT MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 60
HLA TYPING FOR TRANSPLANT MARKET: TRANSPLANT VOLUME BY TYPE, 2023 (NUMBER OF TRANSPLANTS)
TABLE 61
NORTH AMERICA: KEY MACROINDICATORS
TABLE 62
NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 63
NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 64
NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 65
NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 66
US: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 67
US: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 68
US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 69
US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 70
CANADA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 71
CANADA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 72
CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 73
CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 74
EUROPE: KEY MACROINDICATORS
TABLE 75
EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 76
EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 77
EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 78
EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 79
GERMANY: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 80
GERMANY: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 81
GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 82
GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 83
UK: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 84
UK: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 85
UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 86
UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 87
FRANCE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 88
FRANCE: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 89
FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 90
FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 91
SPAIN: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 92
SPAIN: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 93
SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 94
SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 95
ITALY: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 96
ITALY: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 97
ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 98
ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 99
REST OF EUROPE: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 100
REST OF EUROPE: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 101
REST OF EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 102
REST OF EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 103
ASIA PACIFIC: KEY MACROINDICATORS
TABLE 104
ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105
ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 106
ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 107
ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 108
CHINA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 109
CHINA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 110
CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 111
CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 112
INDIA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 113
INDIA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 114
INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 115
INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 116
JAPAN: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 117
JAPAN: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 118
JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 119
JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 120
AUSTRALIA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 121
AUSTRALIA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 122
AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 123
AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 124
SOUTH KOREA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 125
SOUTH KOREA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 126
SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 127
SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 128
REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 129
REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 130
REST OF ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 131
REST OF ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 132
LATIN AMERICA: KEY MACROINDICATORS
TABLE 133
LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 134
LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 135
LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 136
LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 137
BRAZIL: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 138
BRAZIL: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 139
BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 140
BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 141
MEXICO: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 142
MEXICO: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 143
MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 144
MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 145
REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 146
REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 147
REST OF LATIN AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 148
REST OF LATIN AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 149
MIDDLE EAST & AFRICA: KEY MACROINDICATORS
TABLE 150
MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 151
MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 152
MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 153
MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 154
GCC COUNTRIES: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 155
GCC COUNTRIES: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 156
GCC COUNTRIES: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 157
GCC COUNTRIES: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 158
REST OF MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 159
REST OF MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 160
REST OF MIDDLE EAST & AFRICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 161
REST OF MIDDLE EAST & AFRICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 162
OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN HLA TYPING FOR TRANSPLANT MARKET
TABLE 163
HLA TYPING FOR TRANSPLANT MARKET: DEGREE OF COMPETITION
TABLE 164
HLA TYPING FOR TRANSPLANT MARKET: REGION FOOTPRINT
TABLE 165
HLA TYPING FOR TRANSPLANT MARKET: PRODUCT & SERVICE FOOTPRINT
TABLE 166
HLA TYPING FOR TRANSPLANT MARKET: TECHNOLOGY FOOTPRINT
TABLE 167
HLA TYPING FOR TRANSPLANT MARKET: APPLICATION FOOTPRINT
TABLE 168
HLA TYPING FOR TRANSPLANT MARKET: END-USER FOOTPRINT
TABLE 169
HLA TYPING FOR TRANSPLANT MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
TABLE 170
HLA TYPING FOR TRANSPLANT MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT & SERVICE AND REGION
TABLE 171
HLA TYPING FOR TRANSPLANT MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
TABLE 172
HLA TYPING FOR TRANSPLANT MARKET: DEALS, JANUARY 2022–APRIL 2025
TABLE 173
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 174
THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 175
THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025
TABLE 176
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–APRIL 2025
TABLE 177
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–APRIL 2025
TABLE 178
ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 179
ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 180
ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–APRIL 2025
TABLE 181
QIAGEN: COMPANY OVERVIEW
TABLE 182
QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 183
QIAGEN: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2025
TABLE 184
QIAGEN: DEALS, JANUARY 2022–APRIL 2025
TABLE 185
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 186
BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 187
BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2025
TABLE 188
F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 189
F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 190
F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2022–APRIL 2025
TABLE 191
CAREDX, INC.: COMPANY OVERVIEW
TABLE 192
CAREDX, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 193
CAREDX, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
TABLE 194
CAREDX, INC.: DEALS, JANUARY 2022–APRIL 2025
TABLE 195
WERFEN: COMPANY OVERVIEW
TABLE 196
WERFEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 197
WERFEN: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2025
TABLE 198
WERFEN: DEALS, JANUARY 2022–APRIL 2025
TABLE 199
DIASORIN S.P.A.: COMPANY OVERVIEW
TABLE 200
DIASORIN S.P.A.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 201
DIASORIN S.P.A.: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025
TABLE 202
TBG BIOTECHNOLOGY CORP.: COMPANY OVERVIEW
TABLE 203
TBG BIOTECHNOLOGY CORP.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 204
TBG BIOTECHNOLOGY CORP.: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025
TABLE 205
TBG BIOTECHNOLOGY CORP.: DEALS, JANUARY 2022–APRIL 2025
TABLE 206
FUJIREBIO: COMPANY OVERVIEW
TABLE 207
FUJIREBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 208
FUJIREBIO: DEALS, JANUARY 2022–APRIL 2025
TABLE 209
BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
TABLE 210
BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 211
EUROBIO SCIENTIFIC: COMPANY OVERVIEW
TABLE 212
EUROBIO SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 213
EUROBIO SCIENTIFIC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
TABLE 214
EUROBIO SCIENTIFIC: DEALS, JANUARY 2022–APRIL 2025
TABLE 215
PACBIO: COMPANY OVERVIEW
TABLE 216
PACBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 217
PACBIO: PRODUCT APPROVALS AND UPDATES, JANUARY 2022–APRIL 2025
TABLE 218
PACBIO: DEALS, JANUARY 2022–APRIL 2025
TABLE 219
BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW
TABLE 220
BAG DIAGNOSTICS GMBH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 221
CREATIVE BIOLABS: COMPANY OVERVIEW
TABLE 222
CREATIVE BIOLABS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 223
HISTOGENETICS LLC: COMPANY OVERVIEW
TABLE 224
SCISCO GENETICS, INC.: COMPANY OVERVIEW
TABLE 225
INNO-TRAIN DIAGNOSTIK GMBH: COMPANY OVERVIEW
TABLE 226
BIONOBIS: COMPANY OVERVIEW
TABLE 227
TAKARA BIO INC.: COMPANY OVERVIEW
TABLE 228
KRISHGEN BIOSYSTEMS: COMPANY OVERVIEW
TABLE 229
SCIENCELL RESEARCH LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 230
PROIMMUNE LTD.: COMPANY OVERVIEW
TABLE 231
ALPHA BIOTECH LIMITED: COMPANY OVERVIEW
TABLE 232
BIOFORTUNA LIMITED: COMPANY OVERVIEW
FIGURE 1
HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2
HLA TYPING FOR TRANSPLANT MARKET: YEARS CONSIDERED
FIGURE 3
HLA TYPING FOR TRANSPLANT MARKET: RESEARCH DESIGN
FIGURE 4
HLA TYPING FOR TRANSPLANT MARKET: KEY PRIMARY SOURCES
FIGURE 5
HLA TYPING FOR TRANSPLANT MARKET: KEY INSIGHTS FROM PRIMARIES
FIGURE 6
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 7
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 8
RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 9
MARKET SIZE ESTIMATION FOR HLA TYPING FOR TRANSPLANT MARKET: COMPANY REVENUE ESTIMATION
FIGURE 10
REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC. (2024)
FIGURE 11
HLA TYPING FOR TRANSPLANT MARKET: COMPANY REVENUE- AND PROCEDURE-BASED MARKET ESTIMATION APPROACH
FIGURE 12
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 13
HLA TYPING FOR TRANSPLANT MARKET: DATA TRIANGULATION
FIGURE 14
HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
FIGURE 15
HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
FIGURE 16
HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 17
HLA TYPING FOR TRANSPLANT MARKET: REGIONAL SNAPSHOT
FIGURE 18
IMPROVED HEALTHCARE INFRASTRUCTURE AND FAVORABLE GOVERNMENT INITIATIVES TO DRIVE MARKET
FIGURE 19
US AND REAGENTS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
FIGURE 20
EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD
FIGURE 21
CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030
FIGURE 22
HLA TYPING FOR TRANSPLANT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 23
HLA TYPING FOR TRANSPLANT MARKET: VALUE CHAIN ANALYSIS
FIGURE 24
HLA TYPING FOR TRANSPLANT MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 25
HLA TYPING FOR TRANSPLANT MARKET: ECOSYSTEM ANALYSIS
FIGURE 26
HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR HS CODE 3822 (2020–2024)
FIGURE 27
HLA TYPING FOR TRANSPLANT MARKET: IMPORT SCENARIO FOR HS CODE 3822 (2020–2024)
FIGURE 28
HLA TYPING FOR TRANSPLANT MARKET: TOP PATENT APPLICANTS/ OWNERS (JANUARY 2014–DECEMBER 2025)
FIGURE 29
AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY TYPE, 2023–2024 (USD THOUSAND)
FIGURE 30
AVERAGE SELLING PRICING TREND OF REAGENTS, BY TYPE, 2022–2024 (USD THOUSAND)
FIGURE 31
AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY REGION, 2022–2024 (USD THOUSAND)
FIGURE 32
HLA TYPING FOR TRANSPLANT MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 33
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
FIGURE 34
KEY BUYING CRITERIA FOR MAJOR END USERS
FIGURE 35
HLA TYPING FOR TRANSPLANT MARKET: TRENDS/DISRUPTIONS I MPACTING CUSTOMERS’ BUSINESSES
FIGURE 36
HLA TYPING FOR TRANSPLANT MARKET: FUNDING AND NUMBER OF DEALS, 2019–2023
FIGURE 37
HLA TYPING FOR TRANSPLANT MARKET: NUMBER OF DEALS, BY KEY PLAYER, 2019–2023
FIGURE 38
HLA TYPING FOR TRANSPLANT MARKET: VALUE OF DEALS, BY KEY PLAYER, 2019–2023 (USD)
FIGURE 39
AI USE CASES IN HLA TYPING FOR TRANSPLANT MARKET
FIGURE 40
NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET SNAPSHOT
FIGURE 41
ASIA PACIFIC: HLA TYPING FOR TRANSPLANT MARKET SNAPSHOT
FIGURE 42
REVENUE ANALYSIS OF KEY PLAYERS IN HLA TYPING FOR TRANSPLANT MARKET (2020–2024)
FIGURE 43
MARKET SHARE ANALYSIS OF PLAYERS IN HLA TYPING FOR TRANSPLANT MARKET (2024)
FIGURE 44
HLA TYPING FOR TRANSPLANT MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 45
HLA TYPING FOR TRANSPLANT MARKET: COMPANY FOOTPRINT
FIGURE 46
HLA TYPING FOR TRANSPLANT MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 47
EV/EBITDA OF KEY VENDORS
FIGURE 48
5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 49
HLA TYPING FOR TRANSPLANT MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 50
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
FIGURE 51
ILLUMINA, INC.: COMPANY SNAPSHOT
FIGURE 52
QIAGEN: COMPANY SNAPSHOT
FIGURE 53
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
FIGURE 54
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
FIGURE 55
CAREDX, INC.: COMPANY SNAPSHOT
FIGURE 56
DIASORIN S.P.A.: COMPANY SNAPSHOT
FIGURE 57
BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
FIGURE 58
EUROBIO SCIENTIFIC: COMPANY SNAPSHOT
FIGURE 59
PACBIO: COMPANY SNAPSHOT
Growth opportunities and latent adjacency in HLA Typing for Transplant Market